ACS Chemical Biology · 2013 · 155 citations · 22 references
Life SciencesMedicinal ChemistryPharmacologyDrug DesignProtein-protein InteractionsStructural BiologyCyclin-dependent KinasesLigand BindingMacromolecular Structure DeterminationProtein StructureProtein-ligand BindingProtein-protein RecognitionBromodomain InhibitionBromodomain ProteinsCdk InhibitorsChemical Space DesignCyclin-dependent Kinase InhibitorsKinase InhibitorsProtein Kinase Inhibitors
Bromodomain-containing proteins are considered atypical kinases, but their potential to interact with kinase inhibitors is unknown. Dinaciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), which recently advanced to Phase III clinical trials for the treatment of leukemia. We determined the crystal structure of dinaciclib in complex with CDK2 at 1.7 Å resolution, revealing an elaborate network of binding interactions in the ATP site, which explains the extraordinary potency and selectivity of this inhibitor. Remarkably, dinaciclib also interacted with the acetyl-lysine recognition site of the bromodomain testis-specific protein BRDT, a member of the BET family of bromodomains. The binding mode of dinaciclib to BRDT at 2.0 Å resolution suggests that general kinase inhibitors ("hinge binders") possess a previously unrecognized potential to act as protein-protein inhibitors of bromodomains. The findings may provide a new structural framework for the design of next-generation bromodomain inhibitors using the vast chemical space of kinase inhibitors.
22
Overview of the<i>CCP</i>4 suite and current developments
Martyn Winn, Charles Ballard, Kevin Cowtan et al. · Acta Crystallographica Section D Biological Crystallography · 2011 · 12.6K citations · Full text
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text